CLINICAL ROLE -
Access to PCSK9 Inhibitors Still Restricted
At the American College of Cardiology Scientific Session, a study of prescriptions for PCSK9 inhibitors confirms what doctors say about trying to get their patients access to the cholesterol drug.
Read More
Low-Dose Xarelto More Effective Than Aspirin Preventing Blood Clots
Study compares common treatment options to prevent recurrent venous thromboembolism.
Study: PCSK9 Inhibitor Reduces Cardiovascular Death by 25% in One Year
Evolocumab offers a 25% reduction in cardiovascular (CV) death, heart attack, or stroke after the first year.